Busulfan and melphalan are cytotoxic DNA alkylating agents that are used in many hematopoietic stem cell transplantation (HCT) conditioning regimens. We report the development of an assay using turbulent flow liquid chromatography (TFLC) and tandem mass spectrometry to simultaneously measure the concentration of busulfan (Bu) and melphalan (Mel) in human plasma. The method involves precipitating proteins in the plasma specimen with an organic solvent containing deuterated internal standards of both compounds. Following centrifugation, an aliquot of the supernatant was injected into the TFLC mass spectrometry system operated in the positive ion mode. The analytical measurement range for both compounds was 10-5000 ng/mL, and with validated dilutions the reportable range was extended to 25,000 ng/mL. Intra-day and inter-day (n = 20 day) precision studies showed a coefficient of variation (CV) of <7% at several concentrations across the measurement range. To determine accuracy recovery studies were performed at several concentrations spanning the measurement range. Recoveries for both compounds were between 98 and 103%. Additionally, busulfan was compared with an existing assay and showed excellent correlation. Experiments were conducted to rule out matrix effects, carryover and interference from endogenous substances. The validated clinically reportable range (CRR) and assay precision will allow this assay to be used clinically to monitor and adjust Mel and Bu levels to ensure better therapeutic outcomes and also to support clinical trials aimed at better defining therapeutic ranges.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6692901PMC
http://dx.doi.org/10.1016/j.jchromb.2019.121711DOI Listing

Publication Analysis

Top Keywords

busulfan melphalan
12
mass spectrometry
12
dna alkylating
8
alkylating agents
8
human plasma
8
measurement dna
4
agents busulfan
4
melphalan human
4
plasma mass
4
spectrometry busulfan
4

Similar Publications

Purpose: More active high-dose chemotherapy (HDC) regimens are needed for autologous stem-cell transplantation (ASCT) for refractory lymphomas. Seeking HDC enhancement with a poly(ADP-ribose) polymerase (PARP) inhibitor, we observed marked synergy between olaparib and vorinostat/gemcitabine/busulfan/melphalan (GemBuMel) against lymphoma cell lines, mediated by inhibition of DNA damage repair. Our preclinical work led us to clinically study olaparib/vorinostat/GemBuMel with ASCT.

View Article and Find Full Text PDF

Comparison between different reduced intensity conditioning regimens in AML/MDS patients in a Latin American center of adult stem cell transplantation.

Hematology

December 2024

Hematopoietic Stem Cell Transplantation Program, Red de Salud Christus UC - Pontificia Universidad Católica de Chile.

Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for several hematological diseases. Prospective and retrospective studies have associated myeloablative conditioning regimens with increased non-relapse mortality and less intense regimens with disease relapse, leading to similar overall survival rates. Analyze the experience with the different RIC schemes in patients transplanted for AML/MDS in our program.

View Article and Find Full Text PDF
Article Synopsis
  • - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently the best curative option for patients with refractory or relapsed acute myeloid leukemia (AML), but long-term survival rates are still not ideal; researchers are working to improve conditioning regimens like the new MCBC (Melphalan, Cladribine, Busulfan, Cyclophosphamide).
  • - In a study involving 56 patients treated from July 2020 to January 2022, the 2-year overall survival rate was 60.7% and relapse-free survival rate was 57.1%, with a median follow-up of about 2.3 years.
  • - Key findings highlighted that patients
View Article and Find Full Text PDF

High-dose melphalan at 200 mg/m (MEL-200) is the standard conditioning regimen before autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM). Busulfan (BU) and cyclophosphamide (CY) can be used as alternatives when MEL is unavailable. However, most studies on BU/CY conditioning regimens were conducted before proteasome inhibitors (PIs) and immunomodulatory drugs (IMIDs) were available.

View Article and Find Full Text PDF

Reduced Intensity Conditioning Prior Autologous Stem Cell Transplantation in Elderly DLBCL Patients.

Eur J Haematol

January 2025

Department of Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

High-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) is widely used in patients with diffuse large B-cell lymphoma. HDCT/ASCT is associated with increased morbidity in elderly/unfit patients. We retrospectively evaluated the use of reduced intensity conditioning in DLBCL patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!